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Referat: 
Introduction: In acute myeloid leukemia (AML), leukemia initiating cells exist within the 
CD34+/CD38- cell compartment. They are assumed to be more resistant to chemotherapy, 
enriched in minimal residual disease cell populations, and responsible for relapse.  
Purpose: We evaluated clinical and biological associations and the prognostic impact of a 
high diagnostic CD34+/CD38- cell burden in AML patients receiving an allogeneic stem cell 
transplantation (HSCT) in complete remission. Here, the therapeutic approach is mainly 
based on immunological graft-versus-leukemia effects.  
Methods: Percentage of bone marrow CD34+/CD38- cell burden in 169 AML patients at 
diagnosis was measured using flow cytometry. The optimal cutoff of 6% was applied and 
used to evaluate the impact of a high CD34+/CD38- cell burden on outcome.  
Results: The CD34+/CD38- cell burden and was highly variable (median 0.5%, range 0-89% 
of all mononuclear cells). A high CD34+/CD38- cell burden at diagnosis associated with 
worse genetic risk and secondary AML. Patients with a high CD34+/CD38- cell burden had 
shorter relapse-free and overall survival, which may be mediated by residual leukemia 
initiating cells in the CD34+/CD38- cell population, escaping the graft-versus-leukemia effect 
after allogeneic HSCT.  
Conclusion: Evaluating the CD34+/CD38- cell burden at diagnosis may help to identify 
patients at high risk of relapse after allogeneic HSCT. Further studies to understand 
leukemia initiating cell biology and develop targeting therapies to improve outcomes of AML 
patients are needed. 
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Einleitung / Introduction 
Epidemiology and AML diagnosis 
Acute myeloid leukemia (AML) is a disease originating from myeloid progenitor stem cells 
that undergo uncontrolled proliferation and have lost their ability to differentiate. Although 
AML is a rare disease with an incidence of 3.8 cases per 100,000 individuals, it belongs to 
the most frequently diagnosed hematologic disorders1,2 and often affects older individuals 
with a median patient age of around 70 years at diagnosis.1-3 Without therapy, all AML 
patients die within a year after diagnosis,4 and it was not until the 1960ies, with the 
introduction of chemotherapeutic agents such as cytarabine or daunorubicine, when 
remissions were achieved for the first time.5,6  
AML patients present with a variety of nonspecific symptoms including fatigue, bleeding or 
infections, that usually are a result of peripheral cytopenia. With the transition of leukemic 
blasts from bone marrow into the peripheral blood, an elevation of the white blood count 
(WBC) can occur. This may lead to leukostasis if the WBC exceeds 100,000 Gpt/l and 
subsequently cause vascular occlusions. Leukemic cells can also infiltrate extramedullary 
tissue such as the skin or central nervous system (chloroma).1 Besides de novo origins, AML 
often develops following other hematologic disorders – especially myelodysplastic 
syndromes (MDS) and myeloproliferative neoplasia (MPN) – and also occur frequently after 
cytotoxic therapy for unrelated neoplasms. This is particularly the case after the use of 
alkylating agents (with a peak 5-10 years after exposure) or topoisomerase-II inhibitors (with 
a peak 2-3 years after exposure).1 
Morphologic identification, as well as immunohistochemical analyses of blasts in bone 
marrow and peripheral blood allow a discrimination between AML and acute lymphoblastic 
leukemia or MDS. Regarding to the World Health Organization (WHO) classification, the 
diagnosis AML requires the myeloid bone marrow blast count to exceed 20%.7 An exception 
represent the AML-defining aberrations: in the cytogenetic subgroups t(8;21)(q22;q22) and 
		
3	
inv(16)(p13q22) or its variant t(16;16)(p13;q22), in which AML is diagnosed independently of 
the blast count. Besides the sole quantification of blasts in bone marrow and peripheral 
blood, morphologic analysis can divide patients into different French-American-British (FAB) 
types based on the degree of blast maturity and/or differentiation.8 Since the FAB 
classification does not provide prognostic information, today, it is mainly used out of historic 
reasons. 
 
Therapeutic options in AML 
Curative AML treatment approaches are based on cytotoxic therapy and divided into one or 
more induction cycles.1 The purpose of an induction therapy is the achievement of a 
complete remission (CR), that is characterized by normalization of bone marrow blast count 
(<5%) and the recovery of cell counts in peripheral blood.1 Afterwards, consolidation 
therapies are used to maintain CR. Chemotherapeutic substances of choice are cytarabine 
combined with an antracycline (e.g. idarubicine, daunorubicine or mitoxanthrone).9 Besides 
chemotherapy, possible consolidation therapies also include autologous or allogeneic 
HSCT.1  
If an autologous HSCT is planned, patients in CR receive granulocyte-colony stimulating 
factor – with or without a prior cycle of chemotherapy - to mobilize CD34+ hematopoietic 
stem cells (HSCs) into the peripheral blood. During an apheresis, these CD34+ cells are 
collected and frozen. Afterwards, a myeloablative course of chemotherapy is applied and the 
following reinfusion of autologous HSCs secures hematologic regeneration.1 During an 
allogeneic HSCT, HSCs from a sibling or unrelated donor provide this stem cell support.1,10 
Donor selection is based on a matching human leukocyte antigen (HLA) type. Over the 
years, HLA typing evolved with the recognition of new alleles and techniques changing from 
serologic assays for protein detection to molecular methods defining HLA genes by their 
deoxyribonucleic acid (DNA) sequence. Today, high resolution typing of the class I antigens 
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HLA-A, HLA-B and HLA-C and the two class II antigens HLA-DRB1 and HLA-DQB1 are 
referred to as gold standard.11 In contrast to autograft procedures, the therapeutic effect of an 
allogeneic HSCT is believed to - in addition to the conditioning chemotherapy - also rely on 
graft-versus-leukemia (GvL) effects, in which donor lymphocytes recognize disparate minor 
histocompatibility antigens and eliminate surviving tumor cells.12 The GvL effect may 
maintain CR but also harbors the risk of graft versus host disease (GvHD), a condition where 
donor’s lymphocytes react against the patient’s healthy tissue.10,13  
The intensity of distinct conditioning regimens prior to allogeneic HSCT vary substantially 
and till today, no full consensus about a nomenclature was found. The Center for 
International Blood and Marrow Transplant Research (CIBMTR) classified conditioning 
regimens as myeloablative (MAC), reduced-intensity (RIC) or non-myeloablative (NMA) with 
a fluent passage between each other.14 In MAC-HSCT, the administered dosage of 
chemotherapy and/or total body irradiation (TBI) eradicates the host hematopoiesis. Due to 
the high toxicity in this procedure only younger patients without relevant comorbidities are 
eligible.15 With the introduction of NMA conditioning regimens, allogeneic HSCT became 
available for older patients or individuals with relevant comorbidities.16,17 In contrast to MAC 
procedures, considerable less peripheral granulocytopenia is observed and autologous 
regeneration remains possible also without stem cell support. Here, the administered 
chemotherapies and/or TBI have little antileukemic activity17 and the therapeutic success of 
this procedure nearly exclusively relies on GvL effects. As a result of a still existing host bone 
marrow, graft rejection more often occurs after NMA-HSCT and higher dosages and 
combinations of immunosuppressive drugs are needed.17 Finally, the dose intensity of RIC 
regimens lies between MAC and NMA conditionings. Still, the chronology in all HSCT 
regimens is rather similar with peripheral count regenerations approximately 10-14 days after 
HSC infusion.  
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Table 1 provides a summary of definitions and examples for each regimen. 
Table 1: Comparison between MAC, RIC and NMA conditioning regimens, modified 
after Giralt et al.14 and Gyurkocza et al.18  
 
 Myeloablative 
Conditioning 
(MAC) 
Reduced-Intensity 
Conditioning 
(RIC) 
Non-myeloablative 
Conditioning 
(NMA) 
 
Description 
 
 
 
involves a myeloablative 
course of chemotherapy 
no autologous recovery 
possible  
 
consists of alkylating agents 
with or without TBI 
 
 
does not fit MAC or 
NMA conditioning 
characteristics: 
causes potentially 
prolonged cytopenia 
may require stem cell 
support 
 
dose of alkylating 
agents and/or TBI is 
reduced by ≥30% 
compared to MAC 
 
 
 
causes only minimal 
cytopenia 
does not require stem 
cell support 
 
Examples*16,19,20 
 
12 Gy TBI + 
Cyclophosphamide  
2x60 mg/kg 
 
Busulfan 8 mg/kg + 
Fludarabine  
5x30 mg/m2  
 
2 Gy TBI +  
Fludarabine  
3x30 mg/m2 
Required 
Immunosuppression 
	
Intensity/ 
Toxicity 
 
 
Abbreviations: Gy, Gray; kg, body weight (kg); m2, body surface area (m2); TBI, total body irradiation 
* The chosen conditioning examples are the ones frequently used in patients at the University of Leipzig. 
 
Within our publication, we included patients treated with MAC- (12 Gy TBI and 
Cyclophosphamide) and NMA-HSCT (2 Gy TBI and Fludarabine).  
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Genetic risk classification for therapeutic decisions in AML 
AML displays a disease with a large genetic heterogeneity and enormously various clinical 
disease courses. Over the past years, the prognostic relevance of chromosomal aberrations 
and molecular mutations became clearer,21 adding to the long known list of clinical prognostic 
factors such as age, performance status, comorbidities, primary vs. secondary disease or 
WBC and lactate dehydrogenase levels at diagnosis.1,3,22 Today, cytogenetic analyses and 
prevalence of specific mutations are considered within the WHO classification, the most 
commonly used classification for AML (Table 2).7  
Table 2: Adapted from Arber et al:7 The 2016 revision of the WHO classification of AML 
 
Acute myeloid leukemia and related neoplasms 
 
 
Acute myeloid leukemia with recurrent genetic abnormalities 
AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1 
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
APL with PML-RARA 
AML with t(9;11)(p21.3;q23.3); MLLT3-KMT2A 
AML with t(6;9)(p23;q34.1); DEK-NUP214 
AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM 
AML (megakaryoblastic) with t(1;22)(p13.3;q13.3); RBM15-MKL1 
Provisional entity: AML with BCR-ABL1 
AML with mutated NPM1 
AML with biallelic mutations of CEBPA 
Provisional entity: AML with mutated RUNX1 
Acute myeloid leukemia with myelodysplasia-related changes 
Therapy-related myeloid neoplasms 
Acute myeloid leukemia, not otherwise specified 
AML with minimal differentiation 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukemia 
Acute monoblastic/monocytic leukemia 
Pure erythroid leukemia 
Acute megakaryoblastic leukemia 
Acute basophilic leukemia 
Acute panmyelosis with myelofibrosis 
Myeloid sarcoma 
Myeloid proliferations related to Down syndrome 
Transient abnormal myelopoiesis 
Myeloid leukemia associated with Down syndrome 
 
		
7	
Today, genetic risk classifications already influence treatment decisions in the clinical 
practice. There is an agreement that individuals with adverse risk AML should receive an 
allogeneic HSCT if a suitable donor is available. Due to the high cure rates of favorable risk 
AML with chemotherapy and higher treatment-related mortality in allogeneic HSCT, this 
procedure is usually not recommended for patients with favorable risk AML in first CR.23 The 
optimal choice of consolidation treatment for intermediate risk AML remains controversial 
and is being further investigated in clinical trials. For example, a prospective randomized 
Phase III trial currently compares NMA-HSCT to chemotherapy in first CR for elderly patients 
(EudraCT Number 2007-003514-34). Besides the choice between chemotherapy and 
autologous or allogeneic HSCT in first CR, treatment options during relapses or later CRs 
might also include targeted therapies (e.g. novel kinase inhibitors or hypomethylating agents) 
and enrollment in studies testing experimental drugs with their various consequences 
regarding mortality, morbidity, quality of life, and financial costs. Therefore, the choice of the 
optimal treatment for each individual at diagnosis and during remission or relapse remains an 
everyday challenge for physicians.  
In recent years, various risk stratification systems based on chromosomal aberrations – 
which are among the strongest risk factors - have been developed within the different 
cooperative groups (e.g. of the Southwest Oncology Group/Eastern Cooperative Group 
[SWOG/ECOG],23 Medical Research Council [MRC]24 and Cancer and Leukemia Group B 
[CALGB]).25 Although some varieties between the used classifications exist, several general 
statements can be derived.  
About 25% of younger and 7% of older AML patients present with cytogenetics known to 
associate with relatively good outcomes.26 All cooperative groups agree that the core-binding 
factor AMLs t(8;21)(q22;q22) and inv(16)(p13q22) or t(16;16)(p13;q22), as well as acute 
promyelocytic leukemia (APL) defined by the t(15;17)(q22;q21) translocation have a 
favorable prognosis.1,25,27-31 These karyotypes appear more frequently in younger patients 
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and, depending on performance status and comorbidities, can exceed CR rates of 90% and 
long-term remission rates of 60% in younger and 30% in older individuals.1,24-26 
On the other hand, 10-20% of younger and 20-30% of older patients have adverse 
cytogenetic abnormalities, including complex karyotypes (depending on the used 
classification system ≥3 or ≥ 5 unrelated aberrations in one clone), monosomies of 
chromosome 5 or 7 and aberrations on chromosome 3q.1,25,26,28 Besides their higher 
incidence in older patients, they also appear more frequently in secondary or treatment-
related AML.1 For patients with these aberrations, outcome is poor with long-term remission 
rates of 10% for younger and 0-5% for older individuals.24-26,32 Most of the remaining 
cytogenetic aberrations not fitting into the “favorable” or “adverse” risk groups were either not 
further classified (SWOG/ECOG, CALGB) or defined as standard or intermediate risk (MRC).  
Approximately 40-50% of all patients show no aberrant cytogenetics but present with a 
normal 46,XX or 46,XY karyotype (CN). CN-AML was also defined as intermediate risk by all 
three mentioned cooperative groups.23-25 Interestingly, subgroups with distinct long-term 
survival rates ranging from about 20-45% were found CN-AML patients.27,28 Further analyses 
revealed that this striking heterogeneity can at least in part be explained by several 
molecular markers including gene mutations and aberrant gene expressions.33  
Eventually, following the WHO 2008 recommendations,34 three molecular markers were 
included into a novel risk classification system provided by the European LeukemiaNet (ELN) 
in 2010 to further differentiate the prognosis of CN-AML.35 The most frequent gene mutations 
in AML are mutations in the nucleophosmin-1 (NPM1) gene (50-60% of CN-AML cases) 
which have a positive impact on survival.7,36,37 The second mutation with favorable impact 
included into the ELN 2010 classification affects the CCAAT/enhancer-binding protein α 
(CEBPA) gene where N-terminal nonsense and C-terminal frame shift mutations can be 
distinguished.38 CEBPA mutations appear in approximately 15% of CN-AML.34 Internal 
tandem duplications (ITD) of the FMS-related tyrosine kinase 3 (FLT3) gene with variable 
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lengths which occur in 30-40% of CN-AML cases are believed to provide a proliferation and 
survival advantage for AML blasts.34,39 In 2010, the ELN included these three molecular 
markers into risk stratification and proposed the following system (Table 3).  
 
Table 3 (Adapted from Döhner et al.)35: Cytogenetic and molecular genetic risk 
classification in AML according to the ELN 2010 classification 
Genetic group Subsets 
 
Favorable 
 
t(8;21)(q22;q22); RUNX1-RUNX1T1  
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11  
Mutated NPM1 without FLT3-ITD (normal karyotype)  
Mutated CEBPA (normal karyotype) 
 
Intermediate-I 
 
Mutated NPM1 and FLT3-ITD (normal karyotype)  
Wild-type NPM1 and FLT3-ITD (normal karyotype)  
Wild-type NPM1 without FLT3-ITD (normal karyotype) 
 
 
Intermediate-II 
 
 
t(9;11)(p22;q23); MLLT3-MLL  
Cytogenetic abnormalities not classified as favorable or adverse 
 
 
Adverse 
 
inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 t(6;9)(p23;q34); 
DEK-NUP214 
t(v;11)(v;q23); MLL rearranged 
–5 or del(5q)  
–7  
abnl(17p)  
Complex karyotype*  
 
 
* Three or more chromosome abnormalities in the absence of one of the WHO designated recurring 
translocations or inversions, that is, t(15;17), t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23), t(6;9), 
inv(3) or t(3;3); indicate how many complex karyotype cases have involvement of chromosome arms 
5q, 7q, and 17p 
 
While the before mentioned core-binding factor leukemias and APL still were proposed as 
favorable, and deletion 5 or 7, abnormal chromosome 3 or 17p and complex karyotypes as 
adverse risk, CN-AML was further stratified by the molecular markers. CN-AML with a 
CEBPA mutation as well as CN-AML with presence of a NPM1 mutation in the absence of a 
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FLT3-ITD was also defined as favorable risk. All other CN-AML, namely FLT3-ITD with or 
without NPM1 mutations as well as NPM1 wild type without FLT3-ITD were assigned to the 
intermediate-I genetic group. t(9;11)(p22;q23) and all other genetic abnormalities not defined 
as favorable or adverse formed the intermediate-II group. The prognostic significance of the 
ELN 2010 risk classification later was shown by several authors for both younger and older 
AML patients.26,40-42 Given the observed inferior outcomes in patients over the age of 60 
years and the distinct treatment intensities in chemotherapy protocols over or under 60 years 
of age, it was recommended to apply this classification for older and younger individuals 
separately.26,40 
 
Immunophenotyping 
Immunophenotyping constitutes another important modality to elucidate AML phenotypes. 
With the help of this biophysical laser-based technology, cells can be distinguished not only 
by size and granulation, but with the use of fluorescence-labeled antibodies the expression of 
distinct surface proteins can be detected. The clusters of differentiation (CD) mostly are 
membrane-attached glycoproteins expressed on different blood cells. By comparing CD 
molecules expressed on AML cells with the ones normally expressed on healthy progenitor 
or differentiating cells, disease specific phenotypes can be detected. Since many years, 
immunophenotyping is an easy to apply, well established technique and commonly used in 
clinical practice. Today, it is not only a valuable diagnostic and classification tool in AML but 
immunophenotyping was also shown to have prognostic significance and is increasingly 
used for minimal residual disease detection during further disease course.43  
Although its exact function is unknown, the hematopoietic progenitor cell antigen CD34 
functions as cell-cell adhesion factor in bone marrow cells, possibly mediating the attachment 
of human HSCs to bone marrow stroma. The co-expression of CD34 with CD38 indicates 
lineage dedication and is found on over 90% of CD34+ cells.44 The relatively small subset of 
CD34+/CD38- cells in bone marrow contains the majority of a highly primitive cell population 
		
11	
that is assumed to maintain hematopoiesis.45 These HSCs have the potential of self-renewal 
and can also differentiate into all types of mature blood cells.46 CD34+/CD38- cells are able 
to initiate re-transplantable human hematopoiesis when transplanted into Non-Obese 
Diabetic/ Severe Combined Immunodeficiency (NOD/SCID) mice.47 
 
Leukemia Initiating Cells 
Similar to normal hematopoiesis, AML is believed to be hierarchically structured.48 A likewise 
small subset of leukemic cells shows the immature CD34+/CD38- phenotype.48,49 
Interestingly, this population is able to initiate human leukemia not only in one, but also in 
higher generations of NOD/SCID mice. This led to the current understanding that most AML 
clones arise from a primitive cell population, named leukemia initiating or leukemic stem cell 
(LIC), that itself originates from a normal HSC and shares its CD34+/CD38- phenotype.48,50 In 
later studies, both healthy HSCs and LICs were described to be CD44+ and HLA-DR-.51-53 
Other studies indicated that LICs may not only share some phenotype characteristics with 
normal HSCs but also seem to differ substantially from them: the surface expression of CD96 
or CD123 as well as the absence of CD117 has been suggested to have the ability to 
distinguish LICs from healthy HSCs.51,54-57 However, none of these markers has been proven 
the ability to infallibly define the LIC population. Similarly, although LICs and HSCs may 
share some surface marker expressions, LICs show significantly different gene and protein 
expression than healthy HSCs or AML bulk cells58,59 and LIC gene expression signatures 
were already shown to impact on survival of AML patients.60 These surface proteins 
expressed on leukemic CD34+/CD38- cells but not healthy HSCs would not only offer the 
potential to further characterize the LIC population but may also offer new therapeutic 
avenues. Monoclonal antibodies against CD96 to selectively eradicate LICs in vitro use 
before autologous HSCT61 or in vivo as target structure for Fc-engineered mini-antibodies62 
are under development. The monoclonal CD123 antibody CSL362 exhibits cell mediated 
toxicity against LICs and AML bulk cells63 and is currently tested in a phase I trial (Clinical 
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Trials.gov identifier: NCT01632852) on high risk AML patients not eligible for HSCT. CD123 
chimeric antigen receptors (CARS) are also being developed and tested in mice trials.64 
Aurora kinase A is one of the afore mentioned proteins that is believed to be distinctively 
expressed in LICs compared to healthy HSCs,65 and the Aurora kinase A inhibitor MLN8237 
impairs self-renewal, inhibits proliferation and leads to higher apoptosis rates in AML cells.65 
After treatment of NOD/SCID mice resulted in impaired cell engraftment and longer mice 
survival, the orally available substance now entered clinical trials in humans. Further 
potential lies in therapeutically influencing reversible epigenetic changes such as DNA-
methylation or histone deacetylation in LICs, e. g. with the EZH2-inhibitor 3-Deazaneplanocin 
A which promotes apoptosis in LICs but not in healthy HSCs.66,67  
Compared to the majority of circulating, proliferating leukemic blasts or “bulk cells”, LICs are 
relatively resistant to chemotherapeutic agents.68 One reason might be that a large subset of 
CD34+/CD38- cells are metabolically inactive, resting in the G0 cell cycle phase.69 Some 
studies revealed a shorter survival and higher relapse incidences in AML patients with a high 
CD34+/CD38- burden at diagnosis who were treated with chemotherapy.51,70-72 LICs were 
also described to be less immunogenic than AML bulk cells:73 In vitro data showed lower 
lymphocyte proliferation against the CD38- population, as well as decreased IL-2 and IFN-γ 
secretion in the CD34+/CD38- cells. Reasons might be a lower major immune response 
molecule expression on the CD34+/CD38- cell population.71 This supports the assumption 
that a higher LIC population burden at diagnosis may also impact adversely on patients’ 
outcome after allogeneic HSCT. However, until today no study assessed the LIC population 
burden related outcomes in AML patients receiving an allogeneic HSCT, a procedure for 
which the therapeutic impact also relies on cell-derived immunologic effects.  
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Objectives of the here presented study  
1. To analyze the prognostic impact of the bone marrow CD34+/CD38- LIC population 
at diagnosis in AML patients who received an allogeneic HSCT for consolidation 
therapy. 
2. To uncover possible associations of the bone marrow CD34+/CD38- LIC population 
at diagnosis with other clinical and molecular characteristics and prognostic factors in 
AML.  
3. To evaluate whether the bone marrow CD34+/CD38- LIC population at diagnosis 
refines todays risk stratification in AML. 
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Abstract
In acute myeloid leukemia (AML), leukemia-initiating cells exist within the CD341/CD382 cell
compartment. They are assumed to be more resistant to chemotherapy, enriched in minimal resid-
ual disease cell populations, and responsible for relapse. Here we evaluated clinical and biological
associations and the prognostic impact of a high diagnostic CD341/CD382 cell burden in 169
AML patients receiving an allogeneic stem cell transplantation in complete remission. Here, the
therapeutic approach is mainly based on immunological graft-versus-leukemia effects. Percentage
of bone marrow CD341/CD382 cell burden at diagnosis was measured using flow cytometry
and was highly variable (median 0.5%, range 0%–89% of all mononuclear cells). A high CD341/
CD382 cell burden at diagnosis associated with worse genetic risk and secondary AML. Patients
with a high CD341/CD382 cell burden had shorter relapse-free and overall survival which may
be mediated by residual leukemia-initiating cells in the CD341/CD382 cell population, escaping
the graft-versus-leukemia effect after allogeneic transplantation. Evaluating the CD341/CD382
cell burden at diagnosis may help to identify patients at high risk of relapse after allogeneic trans-
plantation. Further studies to understand leukemia-initiating cell biology and develop targeting
therapies to improve outcomes of AML patients are needed.
1 | INTRODUCTION
Hematopoietic stem cells (HSCs) are found in the bone marrow (BM)
and physiologically give rise to all blood cells.1 The phenotype of HSCs
is not well defined, but HSCs have been suggested to be part of the
primitive CD341/CD382 cell population.2 A high amount of the
CD341/CD382 cells seem to rest in the G0 cell cycle phase,3 and are
able to initiate retransplantable hematopoiesis in animal models.4
Acute myeloid leukemia (AML) is a disease originating from the clo-
nal expansion of HSCs or early progenitor cells that have lost the ability
to mature.5 Most researchers agree that similar to the physiological
HSCs, AML-initiating cells—often termed leukemia-initiating cells (LICs)
—also exist within the CD341/CD382 stem cell compartment.6–9 LICs
—opposed to the majority of circulating, proliferating leukemic blasts or
“bulk cells”—are postulated to survive chemotherapy as minimal residual
disease (MRD) and cause AML relapse; their nonproliferative state might
be one reason for resistance to chemotherapy.10–14 When transplanted
into NOD/SCID mice, CD341/CD382 cells of AML patients were able
to initiate leukemia and growth of tumors histologically similar to the
human donor’s neoplasm.7–15
*Presented in part at the Annual Meeting 2014 of The European Hematology
Association (EHA) and the Annual Meeting 2015 of the European Bone
Marrow Transplantation (EBMT) and published in abstract form.
Am J Hematol. 2017;00–00 wileyonlinelibrary.com/journal/ajh VC 2017Wiley Periodicals, Inc. | 1
Received: 1 December 2016 | Revised: 18 January 2017 | Accepted: 23 January 2017
DOI 10.1002/ajh.24663
AJH
Publikation / Publication  
 
  
		
15	
 
Hematopoietic stem cell transplantation (HSCT) offers a curative
treatment option for AML patients if a suitable donor is available. After
achievement of complete remission (CR), HSCT is an established form
of consolidation therapy for patients at high risk of relapse.16 The ther-
apeutic effects of HSCT are mainly based on an immunologic graft-
versus-leukemia (GvL) reaction.17
Previous studies have suggested that a high burden of LICs at
diagnosis of AML patients treated with chemotherapy increased their
relapse probability and associated with inferior outcomes.14,18–20 How-
ever, it is at present unknown whether a high burden of LICs has a sim-
ilar prognostic significance in patients undergoing HSCT. As data
support the assumption that LICs are also less immunogenic than the
leukemic bulk cells,21 evaluation of the pretreatment LIC or the
CD341/CD382 cell burden in AML patients after allogeneic HSCT
might provide important biological and clinical information. The objec-
tive of this study was to determine the prognostic significance of the
CD341/CD382 cell burden at diagnosis in patients undergoing HSCT
and to analyze associations between the CD341/CD382 cell burden
and clinical, cytogenetic, and molecular characteristics to provide fur-
ther biological insights.
2 | PATIENTS AND METHODS
2.1 | Patients and treatment
We analyzed 169 adult AML patients who received HSCT in CR at the
University of Leipzig between June 2001 and July 2013, and for whom
pretreatment BM aspirate material for flow cytometry analysis was
available. All patients received standard cytarabine-based protocol
chemotherapy and were transplanted in the first or second CR (for
details, please see Supporting Information). Written informed consent
for participation in these studies was obtained in accordance with the
Declaration of Helsinki.
Forty-nine (29%) patients received myeloablative conditioning
(MAC), which consisted of cyclophosphamide 60 mg/kg body weight
for 2 days and 12 Gy total body irradiation (TBI),22 whereas 120 (71%)
patients received nonmyeloablative conditioning (NMA), which con-
tained fludarabine 30 mg/m2 for 3 days followed by 2 Gy TBI.23,24 All
patients received granulocyte colony stimulating factor-mobilized
peripheral blood stem cells on day 0. Reasons for NMA, as opposed to
MAC conditioning, were age (patients over 50 years if receiving unre-
lated HSCT [n5102] and patients over 55 years if receiving related
HSCT [n517]) and previous autologous HSCT (n51).
Prior to HSCT, all patients were treated according to age-
dependent chemotherapy protocols (under or over 60 years); for
details, please see Supporting Information. Patients’ characteristics are
shown in Table 1 and Supporting Information, Table S1. At HSCT,
patients had a median age of 62 years (range 19–75) and according to
protocols, patients receiving MAC-HSCT were significantly younger
than patients receiving NMA-HSCT (MAC-HSCT, median 40, range
19–55; NMA-HSCT, median 66, range: 47–75 years; P < .001). Sur-
vival analyses according to conditioning regimes are provided in Sup-
porting Information, Figure S1 and Table S2.
At the time of HSCT, 83% of all patients (84% in MAC-HSCT and
83% in NMA-HSCT) were in their first and 17% (16% in MAC-HSCT
and 18% in NMA-HSCT) were in second CR (for CR definition, see
Supporting Information). Donors were human leukocyte antigen (HLA)-
matched related in 23% of cases (39% in MAC-HSCT and 14% in
NMA-HSCT), while 54% (53% in MAC-HSCT and 58% in NMA-HSCT)
were HLA-matched unrelated and 23% (8% in MAC-HSCT and 28% in
NMA-HSCT) were unrelated with at least one antigen mismatch.
2.2 | Cytogenetics and molecular markers
Pretreatment BM cytogenetic analyses were performed centrally in our
institution. The presence of internal tandem duplication in the FLT3
gene (FLT3-ITD), mutations in the FLT3 tyrosine kinase domain (FLT3-
TKD), and in the NPM1 and CEBPA genes were determined as
described previously.25–27
2.3 | Flow cytometry
For all 169 patients, mononuclear BM cells were assessed for surface
expression of CD34, CD38, and CD34/CD38 at diagnosis. For details,
please see Supporting Information.
2.4 | Definition of clinical end points and statistical
analysis
Statistical analyses were performed using the R statistical software
platform (version 3.0.2). Utilizing the “OptimalCutpoints” package, an
optimal cutoff of 6% was identified that divided the cohort into
patients with a high or a low CD341/CD382 cell burden.
Overall survival (OS) was calculated from HSCT until death from
any cause and relapse-free survival (RFS) was calculated from HSCT to
relapse or death from any cause.
Associations of CD341/CD382 burden with baseline clinical,
demographic, and molecular features were compared using the Krus-
kal–Wallis test and Fisher’s exact test for continuous and categorical
variables, respectively. For time-to-event analyses, survival estimates
were calculated using the Kaplan–Meier method. Groups were com-
pared with the log-rank test. Multivariable analysis is described in Sup-
porting Information.
3 | RESULTS
3.1 | Associations of CD341/CD382 cell burden in
BM at diagnosis with genetic and clinical
characteristics
The CD341/CD382 cell burden at diagnosis was highly variable
(median 0.5%, range 0%–89% of all mononuclear cells). There was no
difference in the CD341/CD382 cell burden between younger
(<60 years) and older (!60 years) patients at diagnosis (P 5 .14, Figure
1A). However, while there were no differences between age groups in
the European LeukemiaNet (ELN),28 Favorable, Intermediate-I, or
Intermediate-II Genetic Groups (Figure 1B–D), older patients in the
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TABLE 1 Clinical characteristics of AML patients treated with HSCT according to CD341/CD382 cell burden at diagnosis (< 6% vs !6%)
Characteristics All patients (n 5 169)
Low CD341/CD382
cell burden (n 5 144)
High CD341CD382
cell burden (n 5 25) P
Age at HSCT, years .14
Median 62 61 63
Range 19–75 19–75 30–74
Sex, n (%) .67
Male 85 (50) 71 (49) 14 (56)
Female 84 (50) 73 (51) 11 (44)
Hemoglobin, g/dL .45
Median 8.6 8.6 9.4
Range 4.5–15.7 4.5–15.7 5.3–13.3
Platelet count, 3109/L .04
Median 63 74 40
Range 2–327 2–327 13–178
WBC count, 3109/L .07
Median 7.9 7.5 35.5
Range 0.7–385 0.7–385 1.1–295
Percentage of blood blasts, % .11
Median 26 22 47
Range 0–98 0–98 2–97
Percentage of BM blasts, % .83
Median 56 56 60
Range 0–95 0–95 0–95
Karyotype, n (%) .39
Abnormal 84 (52) 69 (50) 15 (60)
Normal 79 (49) 69 (50) 10 (40)
ELN genetic group, n (%) .001
Favorable 42 (30) 41 (32) 1 (5)
Intermediate-I 39 (26) 33 (25) 6 (29)
Intermediate-II 32 (21) 30 (23) 2 (10)
Adverse 38 (25) 26 (20) 12 (57)
Disease origin, n (%) .009
De novo 116 (69) 105 (73) 11 (44)
Secondary 53 (31) 39 (27) 14 (56)
MDS 32 25 7
MPN 10 6 4
Solid tumor 11 8 3
NPM1, n (%) .19
Wild-type 109 (74) 90 (71) 19 (86)
Mutated 39 (26) 36 (29) 3 (14)
(continued)
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ELN Adverse Genetic Group had a trend for a higher CD341/CD382
cell burden at diagnosis than younger patients (P 5 .10, median 2.7%
vs 1%, Figure 1E).
In further analyses, we used a 6% cutoff to divide the patients
according to their CD341/CD382 cell burden at diagnosis into low
[<6%, n 5 144 (85%)] and high [!6%, n 5 25 (15%)] burden groups.
Subgroup analyses restricted to patients receiving HSCT in the first CR
are shown in Supporting Information, Table S3 and Figure S5.
At diagnosis, a high CD341/CD382 cell burden associated with
lower platelet counts (P 5 .04), and, by trend, higher white blood cell
(WBC) counts (P 5 .07). Patients developing AML as a secondary dis-
ease following myelodysplastic syndrome, myeloproliferative neoplasia,
or solid tumors were more likely to have a high CD341/CD382 cell
burden at diagnosis than patients with de novo AML (P 5 .009).
Patients with a high CD341/CD382 cell burden were more likely to
have a complex karyotype (!3 cytogenetic abnormalities,28 P 5 .02),
monosomy 5 or deletion of 5q (P 5 .004) or to have a monosomal
karyotype29 (P 5 .004). Among the ELN Genetic Groups, patients with
high CD341/CD382 cell burden at diagnosis were less often classified
in the Favorable (5% vs 32%) and more often in the Adverse (57% vs
20%) Genetic Group (P 5 .001, Table 1). Furthermore, none of the
patients with a high CD341/CD382 cell burden at diagnosis harbored
a CEBPA mutation (P 5 .13).
3.2 | Prognostic value of CD341/CD382 cell burden
at diagnosis
A high CD341/CD382 cell burden at diagnosis associated with
shorter RFS (P < .001, Figure 2A) and OS (P 5 .005, Figure 2B). When
the distinct HSCT-conditioning protocols were regarded separately, we
TABLE 1 (continued)
Characteristics All patients (n 5 169)
Low CD341/CD382
cell burden (n 5 144)
High CD341CD382
cell burden (n 5 25) P
FLT3-ITD, n (%) .77
Absent 114 (78) 99 (79) 15 (75)
Present 32 (22) 27 (21) 5 (25)
CEBPA, n (%) .13
Wild-type 114 (85) 98 (83) 16 (100)
Mutated 20 (15) 20 (17) 0 (0)
Abbreviations: BM, bone marrow; ELN, European LeukemiaNet; FLT3-ITD, internal tandem duplication of the FLT3 gene; HSCT, hematopoietic stem
cell transplantation; MAC, myeloablative; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasia; NMA, nonmyeloablative; WBC, white
blood cell.
FIGURE 1 CD341/CD382 cell burden according to age at diagnosis (<60 years vs !60 years). (A) All patients (n5169) versus healthy
subjects (n520). (B) Favorable ELN genetic risk. (C) Intermediate-I ELN genetic risk. (D) Intermediate-II ELN genetic risk. (E) Adverse ELN
genetic risk
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observed shorter RFS (P 5 .002, Figure 2C) and OS (P 5 .02, Figure
2D) for patients with a high CD341/CD382 cell burden treated with
NMA-HSCT. In the group of MAC-HSCT-treated patients, only four
had a high CD341/CD382 cell burden at diagnosis preventing further
subanalyses of the MAC-HSCT-treated patients. Three years after
transplantation, 65% of patients with a low diagnostic CD341/CD382
cell burden were alive (including 56% of NMA-HSCT-treated patients)
and 60% relapse-free (including 53% of NMA-HSCT-treated patients).
In contrast, in the group with a high CD341/CD382 cell burden, only
43% of patients were alive (including 39% of NMA-HSCT-treated
patients) and only 24% (including 24% of NMA-HSCT-treated patients)
remained relapse-free after 3 years. The CD341/CD382 cell burden
at diagnosis did also impact on RFS and OS when we restricted our
analysis to patients with normal karyotype or de novo AML (Supporting
Information, Figures S2 and S3). Furthermore, in patients with ELN
Favorable or Intermediate genetic risk who had a high CD341/CD382
cell burden at diagnosis, we observed a trend for shorter RFS (P 5 .06)
and comparable OS (P 5 .11) to patients within the ELN Adverse
Genetic Group (Supporting Information, Figure S8).
In multivariable analysis (Table 2), a high CD341/CD382 cell bur-
den at diagnosis remained significantly associated with shorter RFS
(P < .001) and shorter OS (P 5 .04) after adjustment for age at HSCT.
The risk of death or an event was about twice as high in patients with
a high diagnostic CD341/CD382 cell burden compared with that of
patients with a low CD341/CD382 cell burden.
4 | DISCUSSION
Similar to normal hematopoiesis, AML cells are thought to emerge
from primitive LICs with the ability of unlimited self-renewal.15,30 The
observation that leukemic CD341/CD382 cells are able to serially
transplant AML in NOD/SCID mice6,14,15 led to the assumption that
the CD341/CD382 BM compartment harbors the LIC population.30
AML bulk cells are often efficiently eradicated by chemotherapeutic
agents. In contrast, LICs show resistance to chemotherapeutic
agents.31,32 LICs exist in a quiescent state within a stem cell niche and
have slow dividing properties.33 Among other biological features, this
FIGURE 2 Outcome of HSCT-treated AML patients according to the CD341/CD382 cell burden at diagnosis (<6% vs !6%). (A) Relapse-
free survival and (B) overall survival for all patients (n5169) and (C) relapse-free survival and (D) overall survival for patients receiving
NMA-HSCT (n5120)
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quiescence and the increased expression of multidrug resistance genes
may explain the occurrence of relapse after cytotoxic therapy.21 Fur-
thermore, there is growing evidence that leukemic CD341/CD382
cells are also less immunogenic than AML bulk cells. Costello et al.21
showed reduced immunogenicity in vitro with lower lymphocyte prolif-
eration against a CD382 population and decreased IL-2 and IFN-g
secretion. Reasons for this observation might be a lower expression of
major immune response molecules in the CD341/CD382 cell popula-
tion. These observations led us to explore the outcomes as well as bio-
logical and clinical characteristics associated with the CD341/CD382
cell burden at diagnosis in AML patients undergoing HSCT.
While three previous studies did not find associations of a high
CD341/CD382 cell burden with cytogenetics,18,19,34 which may be
related to the varying numbers and characteristics of patients analyzed,
we found that patients with a high CD341/CD382 cell burden were
more likely to have poor-risk cytogenetics. In line with these findings,
we also observed an unequal distribution of patients with high and low
CD341/CD382 cell burden in the four ELN Genetic Groups, with
patients with a high CD341/CD382 cell burden being least often clas-
sified in the Favorable and most frequently in the Adverse Group
(Table 1 and Supporting Information, Table S1). Another study
described an association of a CD341/CD382/ALDHhigh LIC pheno-
type cell burden with poor-risk genetics (ELN adverse genetic risk,
monosomal, or complex karyotypes) in a cohort of 98 patients.35
Patients with a high CD341/CD382 cell burden were also more likely
to have secondary AML, which was also found for the patients harbor-
ing a CD341/CD382/ALDHhigh LIC phenotype.35 Thus, the size of
the LIC population might be interconnected and contribute to the
known adverse outcome of AML with adverse cytogenetic risk, for
example, monosomal or complex karyotypes and secondary AML. Fur-
thermore, none of the patients with a high CD341/CD382 cell burden
at diagnosis was CEBPA-mutated compared to 17% of patients with a
low CD341/CD382 cell burden. We did not observe significant asso-
ciations of a high CD341/CD382 cell burden with the presence of
FLT3-ITD or NPM1 mutations in the entire cohort. However, when we
restricted our analysis to patients receiving HSCT in the first CR, none
of the patients with a high CD341/CD382 cell burden at diagnosis
were NPM1 mutated (P 5 .01, Supporting Information, Table S3). A
small number of studies analyzed the LIC population burden at diagno-
sis in the context of molecular markers and, similar to our study, none
found an association with the presence of FLT3-ITD.14,18,19,34 Whereas
Vergez et al.19 did not find an association of the presence of NPM1
mutations with the LIC population burden (defined by
CD341CD38low/2CD1231), Gerber et al.35 described a decreased
frequency of NPM1 mutations in an LIC phenotype defined by
CD341/CD382/ALDHhigh. It is known that CEBPA mutations activate
self-renewal capacity in committed myeloid progenitor cells,36 resulting
in more mature AML phenotypes, and that NPM1 mutations occur in
more mature CD342 AML cells.37 As the presence of mutations in
both genes impact positively on survival in cytogenetically normal
AML,38 the observed associations may indicate an important biological
interaction between CEBPA or NPM1 mutations and the LIC burden at
diagnosis in AML patients.
We were able to show that a high CD341/CD382 cell burden at
diagnosis associated with shorter RFS and OS after HSCT in CR. In
multivariable analysis, the CD341/CD382 cell burden retained its
prognostic value, independently of other known prognostic factors.
Some studies demonstrated that a high burden of LICs at AML diagno-
sis increased the relapse probability after chemotherapy and associated
with worse outcomes in different patient cohorts.13,18–20,35 In general,
these studies described a wide range of diagnostic BM CD341/
CD382 cells, from 0.01% up to 71%, in AML patients, similar to the
findings in our study. Van Rhenen et al.14 found the diagnostic
CD341/CD382 cell burden of AML patients associated with a higher
MRD frequency evaluated by flow cytometry after chemotherapy,
shorter OS, RFS, and disease-free survival (DFS). Hwang et al.34
described a higher CD341/CD382 cell burden at diagnosis in patients
who did not achieve a CR after one course of chemotherapy. Khan
et al.20 showed lower CR rates and shorter OS for patients over 60
years of age with a higher diagnostic CD341/CD382 cell burden in
blood, but not in BM. Other studies further characterized the analyzed
LIC population. Vergez et al.19 demonstrated that a high
CD341CD38low/2CD1231 cell burden associated with a lower CR
rate, shorter DFS, and shorter OS. Wang et al.18 performed flow
cytometry on FISH-preselected blasts in AML with abnormal karyotype
and demonstrated a shorter OS and RFS and higher relapse rates in
patients with a high FISH1/CD341/CD382 cell burden at diagnosis.
In these studies, the chosen cutoffs to define a high LIC burden were
those with the most significant outcome impact and ranged from 1%
to 15%.14,18–20 This stands in line with our finding with an optimal
TABLE 2 Multivariable outcome analyses of 169 AML patients treated with HSCT according to the CD341/CD382 burden at diagnosis
Relapse-free survival Overall survival
Variable HRa 95% CI P HRa 95% CI P
Age at the time of HSCT 1.03 1.01–1.05 .007 1.05 1.02–1.08 <.001
CD341/CD382 cell burden at diagnosis (!6% vs <6%) 2.44 1.46–4.08 <.001 1.86 1.05–3.37 .04
Abbreviations: CI, confidence interval; HSCT, hematopoietic cell transplantation; HR, hazard ratio; MAC, myeloablative; NMA, nonmyeloablative.
aHR <1 (>1) indicate lower (higher) risk for an event for the first category listed for the dichotomous variables and for the higher values of the contin-
uous variables.
Variables considered in the models were those significant at a5 0.20 in univariable analyses. Variables considered were sex, disease origin (de novo vs
secondary), ELN classification, platelet count at diagnosis, blast count in bone marrow at diagnosis, CD341/CD382 burden at diagnosis, age at HSCT,
disease status at HSCT (first vs second CR), HLA match (antigen match vs mismatch), and HLA donor type (related vs unrelated).
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cutoff at 6% but also significant outcome differences using a 2%, 7.5%,
or 10% cutoff (Supporting Information, Figure S4). Gerber et al.35
showed lower CR rates and shorter EFS and OS in patients with a
more immature LIC phenotype (CD341/CD382/ALDHhigh vs
CD341/CD382/ALDHintermediate vs CD342). However, within these
studies, only 16%–47% of all patients and only younger individuals
underwent HSCT, and none of the studies separately investigated the
outcome of a larger cohort of HSCT-treated patients, for whom the
GvL effect is thought to provide a continuous impact on residual dis-
ease. To our knowledge, this study is the first to show an adverse out-
come of patients with a high LIC-containing cell population at diagnosis
in a larger cohort treated with HSCT as consolidation therapy. Further-
more, the majority of AML patients we analyzed received an NMA-
conditioning protocol,23,39 for which the therapeutic effect is nearly
exclusively based on the GvL effect. The aforementioned reduced
immunogenicity of LICs observed by Costello et al.21 is supported by
our finding that HSCT may not be able to fully overcome the described
poor prognosis of a high LIC burden at diagnosis. Clinically, not unlike
cytotoxic agents, the GvL effect may primarily impact on AML bulk
cells, and LICs within their BM niche may at least partly be able to
evade the GvL effect. This observation helps to deepen our under-
standing why after HSCT in CR, some AML patients remain in remis-
sion while others do not.
We also compared the CD341/CD382 cell burden in AML
patients at diagnosis to the CD341/CD382 BM cell counts during dis-
ease course (in CR before HSCT, at day 28 after HSCT, at relapse) and
to that of 20 healthy individuals (for details, see Supporting Informa-
tion). The CD341/CD382 cell counts of AML patients in CR were
comparable to or even lower than the CD341/CD382 cell count in
the healthy cohort and no significant difference was observed between
patients with a high or a low CD341/CD382 cell burden at diagnosis.
Furthermore, the CD341/CD382 cell counts were higher during AML
relapse and comparable to the CD341/CD382 cell burden at diagno-
sis. For details, see Supporting Information, Figure S9. However, as
healthy HSCs also show the CD341/CD382 phenotype, this popula-
tion alone does not seem to present a suitable marker for risk assess-
ment in CR or MRD detection.
A high CD341/CD382 cell burden at AML diagnosis independ-
ently associated with worse outcomes in patients undergoing HSCT
suggesting that determination of the CD341/CD382 cell burden at
diagnosis may provide a simple and widely available method to improve
risk stratification in AML patients. This may help to identify patients in
need of closer remission monitoring and possibly adjustment of thera-
peutic approaches, for example, tapering of immunosuppressant agents
after HSCT. However, prospective studies to validate our findings are
needed.
Given the inferior outcomes of AML patients with a high CD341/
CD382 cell burden at diagnosis that we and others14,18–20,34,35
observed, regardless of HSCT as a consolidating therapy, new strat-
egies to target LICs may improve survival. For example, the ability to
target the CD341/CD382 cell population was shown for Gemtuzu-
mab ozogamicin,34 and in vitro combination with tipifarnib suggested
synergistic effects, especially on the LIC population.40 Even though
some evidence points to an intraindividual and interindividual hetero-
genic LIC phenotype,35 some surface markers such as CD123,34,41,42
CD96,43 or CD11744 may be able to discriminate between healthy
HSCs and AML LICs, and ways to therapeutically exploit these pheno-
type differences are under investigation.45,46 As CD123 seems to be
expressed on LICs rather than HSCs, another promising therapy are T-
cells expressing CD123-specific chimeric antigen receptors with high
effector activity against AML cell lines and patient samples in vitro
without affecting granulocyte or erythroid colonies.47 Further potential
therapeutic targets may be identified from genes and proteins differen-
tially expressed in LICs compared to AML bulk cells or healthy
HSCs.9,48–50 Combining therapeutic approaches derived from these
studies with chemotherapy and/or HSCT may help to improve out-
comes—especially for those patients who have a high diagnostic
CD341/CD382 cell burden.
In conclusion, our data demonstrate that the negative prognostic
impact of a high CD341/CD382 cell burden at diagnosis seems not to
be easily overcome by the GvL effect after HSCT in AML patients. In
multivariable analysis, a high CD341/CD382 cell burden at diagnosis
was an independent factor for shorter RFS and OS, likely mediated by
LICs within the CD341/CD382 cell population escaping the GvL
effects of HSCT. However, HSCT versus non-HSCT studies will be
needed to evaluate whether patients with a high CD341/CD382 cell
burden at diagnosis might benefit from a HSCT as consolidation ther-
apy, despite their worse outcome than patients with a low burden at
diagnosis. Determination of the CD341/CD382 cell burden at AML
diagnosis may help to improve risk stratification, adjust disease moni-
toring and treatment, especially that it is widely available and relatively
inexpensive. Finally, novel therapeutic agents targeting AML LICs
within the CD341/CD382 cell population may help to improve out-
comes of these patients.
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SUPPLEMENTARY DATA 
M. Jentzsch et al.: Prognostic Impact of the CD34+/CD38- Cell Burden 
in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem 
Cell Transplantation 
 
Further genetic and HSCT related information 
Additional cytogenetic and biological information and hematopoietic stem cell transplantation 
(HSCT) related information are shown in Supplementary Table SI. 
 
Treatment protocols  
Sixty-eight (91%) patients diagnosed with acute myeloid leukemia (AML) at the age of 60 years 
or younger received induction and consolidation therapy according to the AML 2002 study 
(#061, ClinicalTrials.gov Identifier: NCT01414231), six (8%) patients received chemotherapy 
within the PKC412 protocol (ClinicalTrials.gov Identifier: NCT00111345) and one patient (1%) 
was diagnosed with AML as a child and treated within the AML BFM-2014 study 
(ClinicalTrials.gov Identifier: NCT00651261).  
Among AML patients older than 60 years, 91 (97%) were treated within the AML 2004 (#069, 
ClinicalTrials.gov Identifier:  NCT01497002) study and 3 (3%) patients were treated within the 
AML 2004 (#069, ClinicalTrials.gov Identifier:  NCT01497002) protocol and additionally received 
demethylating agents (azacitidine).  
Patients harboring a core-binding factor AML received an allogeneic HSCT in second complete 
remission (CR) or according to patients’ choice in first CR if a suitable donor was available. 
 
Definition of complete remission 
Complete remission (CR) was defined as the presence of <5% of blasts in bone marrow (BM), 
neutrophils >1.0 x 109/L, platelets > 100 x 109/L, absence of blasts with Auer rods, 
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independence of blood transfusion and no extramedullary disease [1]. The presence of CR was 
confirmed within 28 days prior to HSCT by BM and peripheral blood analysis.  
 
Prevention of graft-versus-host disease 
Prevention of graft-versus-host disease (GvHD) was different according to the two conditioning 
regimes used. All patients receiving myeloablative conditioning (MAC) were treated with 
cyclosporine A (CyA), starting intravenously with 5 mg/kg body weight (BW) in two daily doses 
from day -1. Blood levels of CyA were measured from day 0 and doses were adjusted for target 
levels of 200 ng/ml. Patients also received methotrexate 15 mg intravenously on days +1, +3, +6 
and +11 after HSCT. Furthermore, patients with an unrelated donor additionally received in vivo 
T-cell depletion with thymoglobulin 2 mg/kg BW per day on days -3 to -1. 
All patients with non-myeloablative conditioning (NMA) received a starting dose of 5 mg/kg BW 
CyA in two daily doses from day -1. Blood levels of CyA were measured from day 0 and doses 
were adjusted for target levels of 200 ng/ml. Additionally, patients with NMA conditioning 
received mycophenolate mofetil (MMF) 3 g per day in three daily doses if receiving unrelated 
HSCT or 2 g per day in two daily doses if receiving related HSCT. CyA was reduced starting on 
day +84 or day +180 following related or unrelated HSCT, respectively, and MMF was stopped 
at day +28 following related HSCT and tapered from days +40 to +96 following unrelated HSCT.  
For all patients after MAC- or NMA-HSCT, immunosuppression was prolonged or extended with 
systemic steroids in cases of GvHD (grade > 2 according to Glucksberg grading system [2]) or 
rapidly reduced in patients who relapsed (≥ 5% blasts in BM).  
 
Incidence of GvHD 
Patients were evaluated for incidence of acute GvHD (aGvHD) and chronic GvHD (cGvHD), 
using established criteria of the Glucksberg grading system [2]. Requirement for aGvHD was 
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engraftment while requirements for cGvHD was engraftment and survival for at least 100 days 
after HSCT.  
Acute GvHD (grade 2-4) appeared in 42 patients (29%), whereas 76 (61%) patients had cGvHD, 
including 20 (16%) patients with limited and 56 (45%) with extended cGvHD. There was no 
difference in aGvHD development between patients with a high and those with a low 
CD34+/CD38- cell burden at diagnosis as well as cGvHD development in patients surviving 
more than 100 days after HSCT (P=.44, Supplementary Table SI). 
 
Cytogenetic Analysis 
Pretreatment BM cytogenetic analyses were performed centrally in our institution using standard 
banding techniques. In cases were no metaphases could be obtained, fluorescence in-situ 
hybridization (FISH) was used to screen for recurrent abnormalities (i.e. del5/5q, del7/7q, 
trisomy 8, inv(3), abn(p53), abn11q23, t(8;21), inv(16) and t(15;17); [n=5]). 
 
Flow cytometry and evaluation of CD34+/CD38- cell count 
EDTA-anticoagulated fresh BM aspirates were obtained from all 169 patients at AML diagnosis 
prior to beginning of chemotherapy. In all samples, surface marker expression was measured 
with the FACSCalibur flow cytometer and analyzed using the CELLQUEST software (Becton 
Dickinson, Heidelberg, Germany). Samples were stored at room temperature and processed 
within 12 hours. One-hundred microliters of BM aspirates were incubated for 15 minutes with 
phycoerythrin-Cy7 (PE-Cy7, CD38) and allophycocyanin (APC, CD34) labeled monoclonal 
antibodies. After erythrocyte lysis, samples were washed in 1 ml of phosphate buffered saline 
(PBS) solution fixed in 500 μl PBS Acid with 1% formaldehyde; 10,000 cells per sample were 
analyzed. 
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Survival of MAC- or NMA-HSCT treated AML patients 
The whole patient cohort had a 5-year relapse-free survival (RFS) rate of 50% [confidence 
interval (CI) 42-59%, Supplementary Figure S1A] and a 5-year overall survival (OS) rate of 57% 
(CI 49-66%, Supplementary Figure S1B). Cumulative Incidence of Relapse (CIR) at 5 years after 
HSCT was 36% and the competing event non-relapse mortality (NRM) at 5 years was 14%. 
RFS, OS, CIR and NRM at 2 and 3 years after HSCT are shown in Supplementary Table SII. 
Median follow-up after HSCT was 3.4 years (range, 0.3-9.9 years). 
Patients receiving MAC-HSCT had a 5-year RFS rate of 60% and a 5-year OS rate of 75% 
(Supplementary Figures S1C, S1D). Furthermore, a NRM affected 4% and CIR was 36% in 
MAC-HSCT treated patients (Supplementary Table SII). Survival and relapse rates are in line 
with those reported in the existing literature [3-7]. Within the older and in part heavily pretreated 
NMA-HSCT cohort, we observed a 5-year RFS rate of 46% and a 5-year OS rate of 49% 
(Supplementary Figures S1E, S1F). NRM was 18% of NMA-HSCT treated patients and CIR was 
36% of patients. (Supplementary Table SII). This data is comparable with the existing literature 
reporting on similar NMA protocols [7-9]. 
Compared with patients receiving NMA-HSCT, those treated with MAC-HSCT had a significantly 
longer RFS (P=.01) and OS (P<.001). There was no significant difference in relapse rates 
between the two conditioning regimes (P=.59).  
 
Multivariable analysis 
We constructed a multivariable proportional hazard model for OS and RFS to evaluate the 
impact of the CD34+/CD38- cell burden at diagnosis by adjusting for other variables.  
In addition to the CD34+/CD38- cell burden at diagnosis (low vs high), the following variables 
were considered for multivariable analyses: sex, hemoglobin count, platelet count, white blood 
cell count, blast percentages in peripheral blood and BM at diagnosis, AML type (de novo vs 
secondary), European LeukemiaNet (ELN) Genetic Groups, mutation status of the tyrosine 
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kinase domain of the FLT3 gene (FLT3-TKD), age at HSCT, disease status at HSCT (CR1 vs 
CR2), cytomegalovirus (CMV) status of recipient and donor (high risk [+/-] vs all others), HLA 
match (antigen match vs mismatch), HLA donor type (related vs unrelated) and sex of the donor. 
Of these, variables significant at =.20 in univariable analyses were considered for multivariable 
analyses. For OS endpoint, these variables were sex, disease origin (de novo vs secondary), 
ELN classification, platelet count at diagnosis, blast count in bone marrow at diagnosis, 
CD34+/CD38- burden at diagnosis, age at HSCT, HLA match (antigen match vs mismatch) and 
HLA donor type (related vs unrelated) while for RFS endpoint, these variables were disease 
origin (de novo vs secondary), ELN classification, platelet count at diagnosis, blast count in bone 
marrow at diagnosis, CD34+/CD38- burden at diagnosis, age at HSCT, disease status at HSCT 
(first vs second CR) and HLA match (antigen match vs mismatch).  For OS and RFS endpoints, 
hazard ratios with their corresponding 95% CIs were obtained using forward selection analysis 
and indicated for every significant prognostic factor.  
Prognostic value of CD34+/CD38- cell burden at diagnosis 
Utilizing R’s ‘OptimalCutpoints’ package [10] we identified a 6% cut-off to differentiate between 
patients suffering from relapse and patients staying in remission. The CD34+/CD38- cell burden 
at diagnosis, defined using this 6% cut-off value, also had a significant impact on RFS and OS 
when patients with a normal karyotype (P=.002 and P=.05 respectively, Supplementary Figures 
S2A, S2B) and patients diagnosed with de novo AML (P<.001 and P<.001 respectively, 
Supplementary Figures S3A and S3B) were regarded separately. Kaplan-Meier-plots utilizing a 
2%, 7.5% or 10% cut-off point for the CD34+/CD38- cell burden at diagnosis for the entire cohort 
are shown in the supplemental Figures (for 2% cut-off: RFS P=.008, Supplementary Figure S4A 
and OS P=.03, Supplementary Figure S4B; for 7.5% cut-off: RFS P<.001, Supplementary Figure 
S4C and OS P = .01, Supplementary Figure S4D; for 10% cut-off: RFS P=.12 and OS P=.04).  
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CD34+/CD38- cell burden at diagnosis in patients transplanted in first CR 
We performed an analysis restricted to patients transplanted in first CR (n=140; Supplementary 
Table SIII) excluding patients receiving HSCT in second CR. Similar to the whole cohort, we 
observed that patients with a high CD34+/CD38- cell burden at diagnosis were less likely to 
belong to the ELN Favorable Genetic Group (6% vs 32%) and more likely to belong to the ELN 
Adverse Genetic Group (56% vs 21%, P=.01) and were also more likely to harbor secondary 
disease (P=.01). While in the whole patient cohort a lower platelet count and trend for higher 
WBC in patients with a high CD34+/CD38- cell burden at diagnosis was detected, we did not 
observe significant differences in this subanalysis, which is likely a consequence of the lower 
patient numbers in this analysis. However, the median cell counts suggested similar trends 
(median platelet count 38 x109 vs 75 x109 and median WBC 18.9 x109 vs 7.2 x109) as in the 
whole cohort. Furthermore, a significantly lower frequency of NPM1 mutations was observed in 
patients with a high CD34+/CD38- cell burden transplanted in first CR (P=.01). None of the 
patients receiving HSCT in first CR with a high CD34+/CD38- cell burden at diagnosis were 
NPM1 mutated. This observation may be in line with the observation that NPM1 mutations 
commonly appear in AML with the more mature CD34- phenotypes [11].  
Similar to the whole cohort, a high CD34+/CD38- cell burden at diagnosis associated with 
shorter RFS (P=.01, Supplementary Figure S5A) and OS (P=.03, Supplementary Figure S5B) in 
patients transplanted in first CR. When we restricted our analysis to patients receiving NMA-
HSCT in first CR, patients with a high CD34+/CD38- cell burden at diagnosis (n=15) by trend 
had shorter RFS (P=.07, Supplementary Figure S5C) and OS (P=.12, Supplementary Figure 
S5D) compared to individuals with a low burden (n=84).  
 
Landmark analysis for patients surviving longer than 100 days after HSCT  
To exclude possible aGvHD interaction effects, we performed a landmark analysis for the 160 
patients that survived longer than 100 days after HSCT and also observed a significantly shorter 
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RFS (P<.001, Supplementary Figure S6A) and OS (P=.001, Supplementary Figure S6B) for 
patients with a high CD34+/CD38- cell burden at diagnosis.  
 
Prognostic impact of the CD34+/CD38- cell burden within the ELN Genetic Risk groups 
To evaluate whether the CD34+/CD38-cell burden at diagnosis adds prognostic information to 
the current ELN Genetic Risk classification [1], we assessed the prognostic impact of the 
CD34+/CD38- cell burden at diagnosis within the four groups. However, because of the limited 
patient number with a high CD34+/CD38- cell burden within the ELN Favorable (n=1), ELN 
Intermediate-I (n=6) and ELN Intermediate-II Genetic Group (n=2), they were analyzed together. 
Within these three groups, patients with a high CD34+/CD38- cell burden at diagnosis had 
shorter RFS (P<.001, Supplementary Figure S7A) and OS (P=.004, Supplementary Figure S7B) 
while no impact of the CD34+/CD38- cell burden in patients within the ELN Adverse Genetic 
Group (RFS P=.47, OS P=.61) was observed. Interestingly, patients within the ELN Favorable, 
Intermediate-I or Intermediate-II Genetic Groups who had a high CD34+/CD38- cell burden at 
diagnosis showed a trend for shorter RFS (P=.06, Supplementary Figure S8A) and comparable 
OS (P=.11, Supplementary Figure S8B) to patients within the ELN Adverse Genetic Group. This 
data suggests that a high CD34+/CD38- cell burden at diagnosis identifies poor-risk patients 
independently of the ELN Genetic Groups. 
 
Comparison of the CD34+/CD38- cell burden in relapsed patients vs patients in remission 
To investigate whether the CD34+/CD38- cell burden at diagnosis impacts on relapse when no 
cut-off is used, we compared the CD34+/CD38- cell burden in patients who suffered from 
relapse and patients in continuous CR after HSCT. Patients that suffered from relapse had a 
significantly higher CD34+/CD38- cell burden at diagnosis (median 1%, range 0-60%) than 
patients who remained in remission after HSCT (median 0.5%, range 0-89%; P=.01).  
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CD34+ and CD34+/CD38+ cell count at diagnosis 
To evaluate whether the CD34+ or CD34+/CD38+ cell population at diagnosis associates with 
relapse after allogeneic HSCT we compared both populations in patients who suffered from 
relapse and patients in continuous remission after HSCT. Patients who suffered from relapse did 
not show higher CD34+ (P=.31) or CD34+/CD38+ cell counts (P=.44) at diagnosis than patients 
who remained in remission after HSCT. Furthermore, we observed no correlation between the 
CD34+/CD38- cell count and the CD34+ cell count in BM at diagnosis.  
 
The CD34+/CD38- cell population during disease course  
To assess if the adverse outcomes of some AML patients might be mediated by persisting LICs 
in CR after HSCT, for patients with data available, we analyzed the CD34+/CD38- cell count in 
CR up to 28 days before HSCT (32 before MAC-HSCT and 91 before NMA-HSCT), at day +28 
after HSCT for patients in continuous CR (33 after MAC-HSCT and 99 after NMA-HSCT) and at 
first relapse after HSCT (8 after MAC-HSCT and 29 after NMA-HSCT).  
At HSCT, patients had a median CD34+/CD38- cell count of 0.1% (range 0-2%) and on day +28 
after HSCT, relapse-free patients had a median CD34+/CD38- cell count of 0.2% (range 0-
5.1%). The CD34+/38- cell counts in CR before HSCT (P=.86) and at day +28 after HSCT 
(P=.19) did not differ significantly between patients with a high or low CD34+/CD38- cell burden 
at diagnosis. For patients relapsing after HSCT, we found a median CD34+/CD38- cell burden of 
0.5% (0-15%). None of the patients in the low CD34+/CD38- cell burden group at diagnosis had 
a CD34+/CD38- cell count of over 6% at relapse, while in the high CD34+/CD38- cell burden 
group, 3 of 14 patients (21%) also had a CD34+/CD38- cell count of over 6% at relapse 
(Supplementary Figure S9). Since relapsing patients had higher, lower or similar CD34+/CD38- 
cell counts at relapse compared to diagnosis, we observed no association between the absolute 
burden of CD34+/CD38- cells at diagnosis with that at relapse. However, patients with a high 
CD34+/CD38- cell burden at diagnosis also had a trend towards a higher CD34+/CD38- cell 
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burden at relapse compared with those relapsing with a low CD34+/CD38- cell burden at 
diagnosis (median 0.9% vs 0.3%, P=.06). This might suggest a more aggressive phenotype of 
the underlying AML in patients with a high CD34+/CD38- cell burden at diagnosis. Vergez et al. 
[12] evaluated the CD34+CD38low/-CD123+ cell count during relapse in 14 patients and 
observed a similar median burden of these cells at diagnosis (4.5%) and relapse (3.4%), and 
similarly to our findings, Vergez et al. [12] also did not observe an absolute correlation of the 
CD34+CD38low/-CD123+ cell count at diagnosis and relapse. Altogether, these findings suggest 
that indeed the CD34+/CD38- burden at diagnosis seems to affect patients’ outcome and that a 
small amount of LICs within the CD34+/CD38- population that cannot be detected with 
conventional flow cytometry in CR provokes relapse.  
 
Comparison to the CD34+/CD38- cell count of a healthy cohort 
Finally, we compared the CD34+/CD38- cell burden in AML patients at diagnosis to the 
CD34+/CD38- bone marrow cell counts of a healthy cohort (n=20). The healthy cohort and the 
AML patients were evenly matched with regard to sex (P=.81), but the healthy cohort was 
significantly younger than the AML patients (P=.03). We observed a median CD34+/CD38- bone 
marrow cell count of 0.2% (range 0-0.5%) in the healthy cohort. At diagnosis, AML patients had 
a significantly higher CD34+/CD38- cell burden than the healthy cohort (median 0.5% vs 0.2%; 
P=.04). Interestingly, the CD34+/CD38- cell count in AML patients in CR before HSCT was lower 
than the CD34+/CD38- cell count in the healthy cohort (median 0.1% vs 0.2%, P=.05), an effect 
likely caused by the preceding cytoreductive therapies. In AML patients in CR at day +28 after 
HSCT, the CD34+/CD38- cell count was not significantly different from the healthy cohort 
(median 0.2% vs. 0.2%, P=.42). As expected, in AML patients at relapse, the CD34+/CD38- cell 
count was significantly higher than that in the healthy cohort (median 0.5% vs 0.2%, P=.03). This 
was seen especially in patients with a high CD34+/CD38- cell burden at diagnosis (median 0.9% 
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vs 0.2%; P=.009), but not in patients with a low CD34+/CD38- cell burden at diagnosis (median 
0.3% vs 0.2%, P=.18).  
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Supplementary Tables 
Supplemental Table SI. Additional clinical characteristics of NMA-HSCT or MAC-HSCT 
treated AML patients according to the CD34+/CD38- cell burden, < 6% vs ≥ 6%, at 
diagnosis (n=169) 
Characteristic All 
patients 
(n=169) 
low CD34+/CD38- 
cell burden  
(n = 144) 
high CD34+/CD38- 
cell burden  
(n = 25) 
P 
 
Cytogenetic and molecular genetic information 
 
Monosomal karyotype, n (%) 
   Absent 
   Present 
 
146 (92) 
13 (8) 
 
129 (95) 
7 (5) 
 
17 (74) 
6 (26) 
.004 
Complex karyotype, n (%) 
   Absent 
   Present 
 
144 (89) 
17 (11) 
 
126 (92) 
11 (8) 
 
18 (75) 
6 (25) 
.02 
CBF-AML, n (%) 
   Absent 
   Present 
 
146 (92) 
13 (8) 
 
123 (90) 
13 (10) 
 
23 (100) 
0 (0) 
.22 
Trisomy 8, n (%) 
   Absent 
   Present 
 
144 (89) 
18 (11) 
 
123 (89) 
16 (11) 
 
21 (91) 
2 (9) 
1 
-5/del(5q), n (%) 
   Absent 
   Present 
 
150 (92) 
13 (8) 
 
133 (95) 
7 (5) 
 
19 (74) 
6 (26) 
.004 
-7/del(7q), n (%) 
   Absent 
   Present 
 
143 (87) 
21 (13) 
 
123 (88) 
17 (12) 
 
20 (88) 
4 (12) 
.52 
FLT3-TKD, n (%) 
   Absent 
   Present 
 
124 (87) 
18 (13) 
 
106 (86) 
17 (14) 
 
18 (95) 
1 (5) 
.47 
 
HSCT related information 
 
Conditioning, n (%) 
   NMA 
   MAC 
 
120 (71) 
49 (29) 
 
99 (69) 
45 (31) 
 
21 (84) 
4 (16) 
.15 
Remission at HSCT, n (%) 
   CR1 
   CR2 
 
140 (83) 
29 (17) 
 
122 (85) 
22 (15) 
 
18 (72) 
7 (28) 
.15 
HLA type, n (%) 
   Match  
   Mismatch  
 
131 (78) 
38 (22) 
 
114 (79) 
30 (21) 
 
17 (68) 
8 (32) 
.30 
Donor, n (%) 
   Related 
   Unrelated  
 
36 (23) 
133 (77) 
 
33 (23) 
111 (77) 
 
3 (12) 
22 (88) 
.29 
Sex of the donor, n (%) 
   Male 
   Female 
 
110 (66) 
56 (34) 
 
93 (66) 
48 (34) 
 
17 (68) 
8 (32) 
1 
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aGvHD, n (%) 
   Absent  
   Present  
 
104 (71) 
42 (29) 
 
91 (74) 
32 (26) 
 
13 (57) 
10 (43) 
.13 
cGvHD, n (%) 
   Absent 
   Limited 
   Extended  
 
54 (38.7) 
20 (16.1) 
56 (45.2) 
 
47 (41) 
17 (15) 
50 (45) 
 
7 (50) 
3 (21) 
4 (29) 
.44 
 
aGvHD, acute graft-versus-host disease; BM, bone marrow; CBF, core-binding factor; cGvHD, chronic 
graft-versus-host disease; CR, complete remission; FLT3-TKD, tyrosine kinase domain mutation in the 
FLT3 gene; HSCT, hematopoietic stem cell transplantation; HLA, human leukocyte antigen; MAC, 
myeloablative conditioning; NMA, non-myeloablative conditioning. 
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 15 
Supplementary Table SII: RFS, OS, CIR and NRM in MAC-HSCT and NMA-HSCT treated 
patients, n=169 
 RFS  OS  CIR NRM 
 
At 2 years after HSCT 
 
All patients 
(n=169) 
57% 
CI 50-65% 
64% 
CI 56-72% 
30% 
CI 23-37% 
13% 
CI 8-19% 
MAC-HSCT 
(n=49) 
73% 
CI 61-87% 
83.0% 
CI 73-95% 
23% 
CI 12-36% 
4% 
CI 1-13% 
NMA-HSCT 
(n=120) 
51% 
CI 42-61% 
55.2% 
CI 47-65% 
32% 
CI 24-41% 
17% 
CI 11-25% 
 
At 3 years after HSCT 
 
All patients 
(n=169) 
54% 
CI 47-62% 
62% 
CI 55-70% 
32% 
CI 25-40 
14% 
CI 9-20% 
MAC-HSCT 
(n=49) 
70% 
CI 58-85% 
83% 
CI 73-95% 
26% 
CI 14-39% 
4% 
CI 1-13% 
NMA-HSCT 
(n=120) 
47% 
CI 39-58% 
53% 
CI 44-63% 
35% 
CI 26-44% 
18% 
CI 12-26% 
 
At 5 years after HSCT 
 
All patients 
(n=169) 
50% 
CI 42-59% 
57% 
CI 49-66% 
36% 
CI 28-44% 
14% 
CI 9-20% 
MAC-HSCT 
(n=49) 
60% 
CI 45-80% 
75% 
CI 63-91% 
36% 
CI 19-53% 
4% 
CI 1-13% 
NMA-HSCT 
(n=120) 
46% 
CI 37-56% 
49% 
40-60% 
36% 
CI 27-46% 
18% 
CI 12-26% 
 
CI, confidence interval; CIR, cumulative incidence of relapse; MAC, myeloablative conditioning; NMA, 
non-myeloablative conditioning, NRM, non-relapse mortality; OS, overall survival; RFS, relapse-free 
survival.  
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Supplementary Table SIII: Subgroup analysis of associations according to the 
CD34+/CD38- cell burden, < 6% vs ≥ 6%, at diagnosis for patients receiving NMA-HSCT 
or MAC-HSCT in CR1 (n=140) 
Characteristic All CR1 
patients 
(n=140) 
low CD34+/CD38- 
cell burden  
(n = 122) 
high 
CD34+/CD38- cell 
burden (n = 18) 
P 
 
Age at HSCT, years  
   Median 
   Range  
 
61.5 
19.4-75.3 
 
61 
19-75 
 
62 
30-74 
.19 
Sex, n (%) 
   Male    
   Female   
 
68 (49) 
72 (51) 
 
58 (48) 
64 (52) 
 
10 (56) 
8 (44) 
.62 
Hemoglobin, g/dL 
   Median  
   Range  
 
8.5 
4.5-15.7 
 
8.5 
4.5-15.7 
 
9.1 
5.3-13.2 
.83 
Platelet count, x 109/L 
   Median  
   Range  
 
64 
2-327 
 
75 
2-327 
 
38 
13-178 
.18 
WBC count, x 109/L 
   Median  
   Range  
 
7.2 
0.7-385 
 
7.2 
0.7-385 
 
18.9 
1.1-295 
.27 
Percentage of blood blasts, % 
   Median 
   Range 
 
24 
0-98 
 
22 
0-98 
 
39 
2-97 
.42 
Percentage of BM blasts, % 
   Median 
   Range  
 
56.5 
0-95 
 
57 
0-95 
 
52 
0-95 
.43 
Karyotype, n (%) 
   Abnormal 
   Normal 
 
73 (54) 
61 (46) 
 
61 (53) 
55 (47) 
 
12 (67) 
6 (33) 
.32 
ELN Genetic Group, n (%) 
   Favorable 
   Intermediate-I 
   Intermediate-II 
   Adverse 
 
36 (29) 
28 (22) 
29 (23) 
32 (26) 
 
35 (32) 
24 (22) 
27 (25) 
23 (21) 
 
1 (6) 
4 (25) 
2 (13) 
9 (56) 
.01 
Disease origin, n (%) 
   De novo  
   Secondary 
      MDS 
      MPN 
      Solid tumor 
 
93 (66) 
47 (34) 
29 
9 
9 
 
86 (70) 
36 (30) 
23 
5 
8 
 
7 (39) 
11 (61) 
6 
4 
1 
.01 
NPM1, n (%) 
   Wild-type   
   Mutated  
 
93 (76) 
29 (24) 
 
77 (73) 
29 (27) 
 
16 (100) 
0 (0) 
.01 
FLT3-ITD, n (%) 
   Absent 
   Present 
 
99 (83) 
21 (17) 
 
87 (82) 
19 (18) 
 
12 (86) 
2 (14) 
1 
CEBPA, n (%) 
   Wild-type 
   Mutated 
 
94 (86) 
17 (13) 
 
83 (83) 
17 (17) 
 
11 (100) 
0 (0) 
.21 
 
BM, bone marrow; ELN, European LeukemiaNet; FLT3-ITD, internal tandem duplication of the FLT3 
gene; HSCT, hematopoietic stem cell transplantation; MAC, myeloablative; MDS, myelodysplastic 
syndrome; MPN, myeloproliferative neoplasia; NMA, non-myeloablative; WBC, white blood cell.  
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Supplementary Figures 
Supplementary Figure S1 
 
 
Supplementary Figure S1. Outcome for the whole cohort. Relapse-free survival (A) and 
overall survival (B) in NMA- or MAC-HSCT-treated AML patients, n=169; relapse-free 
survival (C) and overall survival (D) in MAC-HSCT-treated AML patients, n=49; relapse-free 
survival (E) and overall survival (F) in NMA-HSCT-treated AML patients, n=120.  
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Supplementary Figure S2 
 
Supplementary Figure S2. Survival in NMA- or MAC-HSCT-treated patients with normal 
karyotype AML according to CD34+/CD38- cell burden at diagnosis, < 6% vs ≥ 6%, 
n=79. (A) Relapse-free Survival. (B) Overall Survival.  
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Supplementary Figure S3 
 
Supplementary Figure S3. Survival in NMA- or MAC-HSCT-treated patients with de 
novo AML according to CD34+/CD38- cell burden at diagnosis, < 6% vs ≥ 6%, n=116. 
(A) Relapse-free Survival. (B) Overall Survival   
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Supplementary Figure S4 
 
Supplementary Figure S4. Survival according to alternative cut-offs. Relapse-free 
Survival (A) and Overall Survival (B) in NMA-HSCT or MAC-HSCT-treated patients according 
to CD34+/CD38- cell burden at diagnosis, <2% vs ≥ 2%, n=169. Relapse-free Survival (C) 
and Overall Survival (D) in NMA- or MAC-HSCT-treated patients according to CD34+/CD38- 
cell burden at diagnosis, <7.5% vs ≥ 7.5%, n=169.  
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Supplementary Figure S5 
 
Supplementary Figure S5. Subanalysis for patients transplanted in CR1. Relapse-free 
Survival (A) and Overall Survival (B) in all patients receiving HSCT in CR1 (n=140) and 
Relapse-free Survival (C) and Overall Survival (D) in patients receiving NMA-HSCT in CR1 
(n=99) according to CD34+/CD38- cell burden at diagnosis, < 6% vs ≥ 6 %. 
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Supplementary Figure S6 
 
 
Supplementary Figure S6. Landmark analysis for patients surviving longer than 100 
days after HSCT. Relapse-free Survival (A) and Overall Survival (B) in NMA- or MAC-
HSCT-treated patients according to CD34+/CD38- cell burden at diagnosis, < 6% vs ≥ 6%, 
n=160.  
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Supplementary Figure S7 
 
 
 
Supplementary Figure S7. Subanalysis for patients with ELN favorable, intermediate-I 
and intermediate-II Genetic Risk. Relapse-free Survival (A) and Overall Survival (B) in in 
NMA- or MAC-HSCT-treated patients according to CD34+/CD38- cell burden at diagnosis,   
< 6% vs ≥ 6 %, n=113. 
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Supplementary Figure S8 
 
Supplementary Figure S8. Comparison between patients with ELN adverse Genetic 
Risk (n=38) and patients with ELN favorable, intermediate-I or intermediate-II Genetic 
Risk and a high CD34+/CD38- cell burden at diagnosis (n=9), < 6% vs ≥ 6%. (A) 
Relapse-free Survival. (B) Overall Survival. 
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Supplementary Figure S9 
 
 
Supplementary Figure S9. CD34+/CD38- cell count at diagnosis and during relapse for 
patients with a low (A) or a high (B) CD34+/CD38- cell burden at diagnosis. (C) 
CD34+/CD38- cell count during disease progression for patients with available flow data at 
time points. 
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Although over the last decades important steps towards understanding the pathogenesis of 
acute myeloid leukemia (AML) have been made, outcomes for most AML patients remain 
vastly improvable. On our way to individualized therapies, risk assessment at diagnosis of 
AML is crucial to estimate individual treatment response and probability of relapse.  
The identification of new prognostic factors can lead to optimized risk stratification, 
adjustment of treatment strategies as well as to the detection of new potential therapeutic 
targets and subsequently may improve prognosis for AML patients. Leukemia initiating cells 
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(LICs) are an immature cell population that is thought to be responsible for the development, 
maintenance, and recurrence of AML. Much effort has been made to describe the phenotype 
of these cells and most researchers agree that LICs express CD34 in the absence of CD38. 
In some studies a high burden of LICs at diagnosis impacted adversely on outcomes when 
AML patients were consolidated with chemotherapy. However, the prognostic impact of a 
high LIC burden in AML patients receiving allogeneic hematopoietic stem cell transplantation 
(HSCT) as consolidation therapy – where the therapeutic effect also relies on graft-versus-
leukemia effects - remained unknown.  
The first objective of the here presented study was to analyze the prognostic impact of the 
bone marrow CD34+/CD38- LIC population at diagnosis in AML patients who received an 
allogeneic HSCT for consolidation therapy.  
Analyzing the CD34+/CD38- cell burden at diagnosis in our HSCT-treated cohort, we 
observed this population to be highly variable, ranging from 0% to 89% of bone marrow cells 
with a median of 0.5% at diagnosis. AML patients with a high CD34+/CD38- cell burden 
(over 6%) at diagnosis had a significantly shorter overall survival (P=.005) and relapse-free 
survival (P<.001). This was also observed when we restricted our analysis to patients with 
normal karyotype, de novo disease or HSCT in first complete remission. 
The observed difference in survival was mediated by a higher cumulative incidence of 
relapse in patients with a higher CD34+/CD38- cell burden at diagnosis (P<.001, Figure 1a). 
In contrast, the cumulative incidence of non-relapse mortality which summarizes HSCT-
related deaths due to graft-versus-host disease or infections, as well as mortality not 
associated with HSCT or relapse was similar in both groups (P=.75, Figure 1b).   
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Figure 1: Cumulative Incidence of relapse (a) and Cumulative Incidence of Non-relapse 
Mortality (b) in 169 AML patients receiving HSCT depending on the CD34+/CD38- 
burden at diagnosis (<6% vs. ≥6%) 
 
 
The second objective of the here presented study was to uncover possible associations of 
the bone marrow CD34+/CD38- LIC population at diagnosis with other clinical and molecular 
characteristics and prognostic factors in AML.  
The patients in our set were well characterized for other clinical and genetic factors 
described in AML. We observed that patients with a higher CD34+/CD38- burden at 
diagnosis had a lower platelet count at diagnosis (P=.04), were also more likely to belong to 
worse ELN 2010 genetic groups (P=.001) and more often had complex (P=.02) or 
monosomal karyotypes (P=.004), for which a dismal prognosis have been described. 
Furthermore, AML with secondary origin following MDS or MPN diagnosis is known to 
associate with a worse prognosis than de novo disease. We also observed a higher 
CD34+/CD38- cell burden in patients with secondary AML (P=.009) compared to de novo 
disease. On the other hand, CEBPA mutations, which frequently occur in AML with favorable 
outcomes were not observed in patients with high CD34+/CD38- cell burden (P=.13).  
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The third objective of our study was to evaluate whether the bone marrow CD34+/CD38- LIC 
population at diagnosis refines todays risk stratification in AML. 
As described above, a high CD34+/CD38- cell burden associated with other known adverse 
prognosticators in AML. Strikingly, a multivariable analysis demonstrated that the 
CD34+/CD38- cell burden at diagnosis impacted on relapse-free and overall survival, 
independently of other prognostic factors. The risk of relapse or death in patients with a high 
CD34+/CD38- cell burden at diagnosis was about twice as high as in patients with a low 
CD34+/CD38- cell burden at diagnosis. This data suggests that the immature CD34+/CD38- 
cell population may contribute to the dismal outcome of patients with adverse karyotypes or 
secondary AML. Finally, we were able to show that patients with favorable or intermediate 
risk according to the ELN 2010 genetic risk classification but a high CD34+/CD38- cell 
burden at diagnosis had a trend for shorter relapse-free survival (P=.06) and comparable 
overall survival (P=.11) as patients within the Adverse ELN 2010 Genetic Group. Thus, a 
high CD34+/CD38- cell burden may be able to identify poor-risk patients also independently 
of the ELN 2010 Genetic Groups. 
In conclusion, we were the first to show that a high burden of a LIC-containing cell population 
at diagnosis also associates with worse outcomes in AML patients who received an 
allogeneic HSCT for consolidation therapy. Strikingly, this observation was independent of 
other known prognostic factors in AML. Our work further improves risk assessment at AML 
diagnosis and points out the need to develop therapies against the clinically important LIC 
population. In the future, LIC-targeted therapies may overcome the adverse impact of a high 
CD34+/CD38- cell burden and improve survival of AML patients. 
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Weiterführende Arbeiten / Future developments  
GPR56 as new LIC marker 
Although the here presented CD34+/CD38- cell phenotype remains the widely accepted LIC 
population, there is ongoing research for new stem cell markers to more precisely define the 
LIC population. With the introduction of experiments using more permissive immunodeficient 
mouse models (e.g. NOD/SCID/IL2r-/-, NOD/SCID/2m-/-), it was suggested that, in some 
cases, the CD34- cell population might also harbor a small amount of cells with LIC potential, 
e.g. in NPM1 mutated AML.74  
Recently, the G protein-coupled receptor 56 (GPR56) was described as a new LIC marker.75 
GPR56 is a G protein-coupled adhesion molecule regulating survival, migration and 
adhesion in various cell types.76 In AML, GPR56 seems to be important for the interaction of 
LICs with the bone marrow stroma, called stem cell niche.75 GPR56 expression was shown 
to be upregulated in healthy hematopoietic stem cells as well as LICs, especially when 
residing in a quiescent state, and downregulated during maturation.77 High GPR56 
expressing AML cells were able to serially transplant leukemia in NOD/SCID mice and thus, 
were functionally validated as LICs.78,79 Interestingly, this property was also found in LICs 
with low or absent CD34 expression, suggesting GPR56 as a new marker with the ability to 
define LICs independently of the CD34 expression.78 
In our here presented study, most patients with a CD34+/CD38- cell burden of 6% or higher 
at diagnosis (15% of the used set) had a dismal outcome. However, within the larger group 
of patients with a lower CD34+/CD38- cell burden (85% of the used set) outcome remained 
highly heterogeneous. Since GPR56 may provide further information on the LIC containing 
AML cell population, we evaluated the diagnostic GPR56 expression at diagnosis in 148 
AML patients with adequate material available in a follow up work.80 Here, we observed a 
correlation of the GPR56 expression with the CD34+/CD38- cell burden (P
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diagnosis. As expected, the GPR56 expression at diagnosis was associated with a higher 
cumulative incidence of relapse after HSCT (P=.02, Figure 2a).  
Since GPR56 was described to define LICs also in the CD34- compartment, we further 
evaluated the GPR56 expression in the subgroup of patients with a low CD34+/CD38- cell 
burden at diagnosis. Interestingly, a high GPR56 expression defined a patient population 
with significantly higher cumulative incidence of relapse compared to patients with a low 
GPR56 expression and a low CD34+/CD38- cell burden (P=.05) but significantly lower 
cumulative incidence of relapse compared to patients with a high CD34+/CD38- cell burden 
at diagnosis (P=.02, Figure 2b).80 
 
Figure 2: Cumulative incidence of relapse according to (a) the GPR56 expression 
status at diagnosis (high vs. low, median cut) and (b) the GPR56 expression status 
(high vs. low, median cut) and the CD34+/CD38- cell burden at diagnosis (high vs. low, 
6% cut)  
 
This observation was confirmed in a multivariable analysis, in which the combined 
information on the LIC burden at diagnosis, defined by the CD34+/CD38- cell burden and the 
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GPR56 expression, significantly impacted on cumulative incidence of relapse after 
adjustment for disease status at HSCT and EVI1 expression at diagnosis. (Table 4).    
Table 4: Multivariable Analysis for CIR in HSCT treated AML patients (n=148) 
Variable Cumulative incidence of Relapse 
HR* 95% CI P 
Leukemia initiating cell population 
(low CD34+/CD38- & low GPR56 vs. low CD34+/CD38- & 
high GPR56 vs. high CD34+/CD38-) 
1.42 1.03-1.98 .035 
Disease status at HSCT 
(CRi vs. CR) 
0.43 0.22-0.85 .016 
EVI1 expression at diagnosis 
(negative vs. positive) 
2.58 1.29-5.15 .007 
 
Abbreviations: CI, confidence interval; CR, complete remission; CRi, complete remission with incomplete 
peripheral recovery; HSCT, hematopoietic cell transplantation; HR, hazard ratio. 
* HR, Hazard ratio, <1 (>1) indicate lower (higher) risk for an event for the first category listed for the dichotomous 
variables and for the higher values of the continuous variables. Variables considered in the models were those 
significant at α=0.20 in univariable analyses. Variables considered were: disease origin (secondary vs. de novo), 
ELN 2010 classification, platelet count at diagnosis, blast count in bone marrow at diagnosis, leukemia initiating 
cell population at diagnosis (low CD34+/CD38- & low GPR56 vs. low CD34+/CD38- & high GPR56 vs. high 
CD34+/CD38-), EVI1 expression at diagnosis (negative vs. positive), age at HSCT, disease status at HSCT (CRi 
vs. CR).  
 
Our data supports the assumption by Pabst et al. that GPR56 may further subdivide the 
CD34+/CD38- LIC compartment and may be an independent LIC marker. In the near future, 
we intend to perform in vitro and in vivo experiments with both cell populations to further 
explore the prognostic value and biological features of this LIC containing AML cell 
population. 
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